Upstream Bio

Inflammation and Allergy


HBM contact: Dr Emil Bujak

Company status: private

Upstream Bio, a clinical-stage biotech company advancing new therapies to treat allergy and inflammation, is developing UPB-101, a clinical-stage monoclonal antibody that inhibits the TSLP receptor.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171